A Study To Assess The Effect Of Linezolid On QTc Interval

• Drug: Placebo
  
  Intravenous, Placebo control for blinding, Normal Saline, Single dose
• Drug: Linezolid 900 mg
  
  Intravenous, 900 mg linezolid, single dose
  Other Name: Zyvox
• Drug: Linezolid 1200 mg
  
  Intravenous, 1200 mg linezolid, single dose
  Other Name: Zyvox
• Drug: Linezolid 600 mg
  
  Intravenous, 600 mg linezolid, single dose
  Other Name: Zyvox
• Drug: Moxifloxacin 400 mg
  
  Oral, 400 mg moxifloxacin, single dose
  Other Name: Avelox

• Placebo Comparator: Cohort 1: Placebo
  
  Intervention: Drug: Placebo
• Experimental: Cohort 1: 900 mg linezolid
  
  Intervention: Drug: Linezolid 900 mg
• Experimental: Cohort 1: 1200 mg linezolid
  
  Intervention: Drug: Linezolid 1200 mg
• Placebo Comparator: Cohort 2: Placebo
  
  Intervention: Drug: Placebo
• Experimental: Cohort 2: 600 mg linezolid
  
  Intervention: Drug: Linezolid 600 mg
• Experimental: Cohort 2: 1200 mg linezolid
  
  Intervention: Drug: Linezolid 1200 mg
• Active Comparator: Cohort 2: 400 mg Moxifloxacin
  
  Intervention: Drug: Moxifloxacin 400 mg

Inclusion Criteria:

• Healthy male and female subjects between the ages of 21 and 55 years.
• Body mass Index (BMI) of 18 to 30 kg/m2; and a total body weight > 45 kg (99 lbs).
• An informed consent document signed and dated.

Exclusion Criteria:

• Evidence or history of clinically significant abnormality.
• 12-lead ECG demonstrating QTc >450 msec at Screening.
• Receiving selective serotonin reuptake inhibitors (SSRIs) and/or sympathomimetic agents.
• Abnormal liver function tests.
• A positive urine drug screen, history of excessive alcohol and tobacco use.